Intercept Pharmaceuticals, Inc. announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. Mr. Bradbury has over 35 years of experience leading global, fast-growing life sciences companies. Dan currently serves as Executive Chairman of Equillium, a biopharmaceutical company he co-founded.

In addition, Mr. Bradbury is a Managing Member of BioBrit, a life sciences consulting and investment firm. Previously, Dan held several senior positions at Amylin Pharmaceuticals, a biopharmaceutical company focused on diabetes and metabolic disorders, including as President and Chief Executive Officer, until its acquisition by Bristol-Myers Squibb Company in August 2012. Prior to joining Amylin, Mr. Bradbury worked at SmithKline Beecham Pharmaceuticals and its predecessor companies for ten years in various sales and marketing positions.

Dan currently serves as a director of Castle Biosciences and Intercept Pharmaceuticals and additionally serves on the board of directors of a number of private companies and philanthropic organizations. In addition, Mr. Bradbury serves on the Keck Graduate Institute?s Board of Trustees and the University of California San Diego?s Rady School of Management Dean?s Advisory Council. Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.